JP2018515514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515514A5 JP2018515514A5 JP2017558660A JP2017558660A JP2018515514A5 JP 2018515514 A5 JP2018515514 A5 JP 2018515514A5 JP 2017558660 A JP2017558660 A JP 2017558660A JP 2017558660 A JP2017558660 A JP 2017558660A JP 2018515514 A5 JP2018515514 A5 JP 2018515514A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- alkyl
- substituted
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160989P | 2015-05-13 | 2015-05-13 | |
| US62/160,989 | 2015-05-13 | ||
| PCT/US2016/031996 WO2016183278A1 (en) | 2015-05-13 | 2016-05-12 | Heteroaryl compounds for kinase inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515514A JP2018515514A (ja) | 2018-06-14 |
| JP2018515514A5 true JP2018515514A5 (enExample) | 2019-06-13 |
| JP6863901B2 JP6863901B2 (ja) | 2021-04-28 |
Family
ID=57249337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558660A Expired - Fee Related JP6863901B2 (ja) | 2015-05-13 | 2016-05-12 | キナーゼ阻害のためのヘテロアリール化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323976A1 (enExample) |
| EP (1) | EP3294712A4 (enExample) |
| JP (1) | JP6863901B2 (enExample) |
| HK (1) | HK1251567A1 (enExample) |
| WO (1) | WO2016183278A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| CN109705117A (zh) * | 2017-10-25 | 2019-05-03 | 南京圣和药业股份有限公司 | 三环类化合物、其制备方法及用途 |
| CN109705118B (zh) * | 2017-10-25 | 2021-12-28 | 南京圣和药业股份有限公司 | 三环类egfr激酶抑制剂的制备方法 |
| CN108191861B (zh) * | 2018-03-01 | 2020-10-02 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 |
| AU2020296620B2 (en) * | 2019-06-20 | 2023-07-13 | Oncobix Co.Ltd. | Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof |
| EP4100409B1 (en) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
| CN115052881B (zh) * | 2020-02-03 | 2024-07-09 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| CN112409192A (zh) * | 2020-11-26 | 2021-02-26 | 启东东岳药业有限公司 | 一种4-氟-2-甲氧基苯胺的纯化方法 |
| PE20240327A1 (es) | 2021-04-13 | 2024-02-22 | Nuvalent Inc | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003000251A1 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel idolinones and uses thereof |
| AU2008314632B2 (en) * | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| ES2645689T5 (en) * | 2008-05-21 | 2025-06-24 | Takeda Pharmaceuticals Co | Phosphorous derivatives as kinase inhibitors |
| US9273077B2 (en) * | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| TWI546290B (zh) * | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| JP5427321B2 (ja) * | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| AU2014337067B2 (en) * | 2013-10-18 | 2019-01-24 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US20170166598A1 (en) * | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| JP6230205B2 (ja) * | 2014-06-19 | 2017-11-15 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| CN107614503B (zh) * | 2015-04-29 | 2020-03-10 | 广东众生药业股份有限公司 | 稠环或三环芳基嘧啶化合物用作激酶抑制剂 |
-
2016
- 2016-05-12 HK HK18111064.8A patent/HK1251567A1/zh unknown
- 2016-05-12 WO PCT/US2016/031996 patent/WO2016183278A1/en not_active Ceased
- 2016-05-12 EP EP16793497.5A patent/EP3294712A4/en not_active Withdrawn
- 2016-05-12 JP JP2017558660A patent/JP6863901B2/ja not_active Expired - Fee Related
- 2016-05-12 US US15/573,211 patent/US20210323976A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515514A5 (enExample) | ||
| JP2018012712A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| PE20230161A1 (es) | Inhibidores de proteinas kras mutantes | |
| IL275762B2 (en) | History of PHENYL-SO2-NH-C(=O)-PHENYL-PIPERAZINE-CH2-1,2-CYCLOHEXANE-BICYCLO[1.1.1]PENTANE and spirit preparations containing them | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2014500265A5 (enExample) | ||
| JP2020503271A5 (enExample) | ||
| MY191938A (en) | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof | |
| CY1114908T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2017533968A5 (enExample) | ||
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| PH12019500804A1 (en) | Liposomal formulation for use in the treatment of cancer | |
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| JP2009541223A5 (enExample) | ||
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
| JP2016527217A5 (enExample) | ||
| JP2016512520A5 (enExample) | ||
| JP2005527587A5 (enExample) |